The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified

Clinical Trial Summary

The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors

1. The main purpose - security and ORR;

2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.

See also
Status	Clinical Trial	Phase
Completed	`NCT00728468` - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Completed	`NCT00768469` - Study Evaluating Safety And Tolerability, Solid Tumor	Phase 1
Recruiting	`NCT04226066` - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04908046` - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06464055` - A Study of GQ1010 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06231550` - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors	Phase 1
Not yet recruiting	`NCT05383703` - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor	Phase 1
Recruiting	`NCT05773937` - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT04328506` - Bioequivalency Study of CM082 Tablet in Healthy Volunteers	Phase 1
Recruiting	`NCT05886374` - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT00958724` - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT05949775` - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors	N/A
Terminated	`NCT02045095` - A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors	Phase 1
Completed	`NCT00884845` - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT05277454` - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT	Phase 1
Active, not recruiting	`NCT03792958` - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors	Phase 1
Withdrawn	`NCT00997360` - Study of PKI-179 Administered Orally to Subjects With Solid Tumors	Phase 1
Completed	`NCT04126668` - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers	Phase 1
Recruiting	`NCT05338957` - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.	Phase 1/Phase 2

NCT number	NCT03047811
Study type	Interventional
Source	Fudan University
Contact	xiang hua wu, doctor
Phone	13482888167
Email	xhwu2011@yahoo.com
Status	Recruiting
Phase	N/A
Start date	August 26, 2016
Completion date	December 31, 2017

The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms